A Case Study and Literature Review on Type IV Spinal Muscular Atrophy with Gastrocnemius Pseudohypertrophy Due to SMN1 Gene Deletion - Scorecard - MDSpire
Advertisement
A Case Study and Literature Review on Type IV Spinal Muscular Atrophy with Gastrocnemius Pseudohypertrophy Due to SMN1 Gene Deletion
Clinical Scorecard: A Case Study and Literature Review on Type IV Spinal Muscular Atrophy with Gastrocnemius Pseudohypertrophy Due to SMN1 Gene Deletion
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Adults, particularly those with progressive muscle weakness and pseudohypertrophy, noting the rarity of Type IV SMA.
Care Setting
Key Highlights
Type IV SMA is rare and often misdiagnosed due to atypical presentations.
Pseudohypertrophy of the gastrocnemius muscle is an uncommon feature.
Diagnosis confirmed through whole-exome sequencing revealing SMN1 gene deletion.
Symptoms include progressive weakness and muscle atrophy.
Disease-modifying therapy is available but may be refused by patients.
Genetic counseling is crucial for affected individuals and families.
Guideline-Based Recommendations
Diagnosis
Utilize whole-exome sequencing for definitive diagnosis of SMA.
Consider clinical history and physical examination findings.
Management
Recommend disease-modifying therapy for SMA when appropriate.
Incorporate genetic counseling and multidisciplinary approaches.
Monitoring & Follow-up
Regular follow-up for symptom progression and response to treatment.
Risks
High risk of misdiagnosis due to overlapping symptoms with other conditions.
Patient & Prescribing Data
Patient may refuse recommended disease-modifying therapies, impacting prognosis.
Clinical Best Practices
Conduct thorough genetic counseling for affected individuals and families.
Be vigilant for atypical presentations of SMA to avoid misdiagnosis.
Incorporate multidisciplinary approaches for management and support.
Provide ongoing education for clinicians to recognize atypical presentations.
